Defense of accuracy Leverage Strand Diagnostics’ know error system to position as a precision patient-safety solution for surgical biopsy workflows, targeting hospitals and pathology groups seeking to reduce misidentification risk and liability.

Regulatory credibility Highlight FBI accreditation and CLIA certification as strong differentiators when approaching medical centers and public agencies with compliance-first procurement criteria for diagnostic and forensic workflows.

Expansion leverage Capitalize on their growth agenda evidenced by a $30M Series A to scale operations; propose scalable cloud-enabled integrations, training, and sales support to rapidly onboard new clients in oncology and pathology networks.

Biopsy workflow fit Propose integration points with biopsy sample tracking, LIMS, and patient record systems to streamline specimen identity verification, reduce biopsy mislabeling, and improve diagnostic turnaround times.

Public-sector potential Given experience processing crime-scene samples for police agencies, explore opportunities for collaboration with governmental pathology labs or forensic units that require robust chain-of-custody, audit trails, and secure data handling.